Skip to content
Investors
Press Releases
About Us
Contact
Science
ALLO and GABA
GAMSAs
The GABA-A Receptor
Sepranolone
What is Sepranolone?
ALLO and GABA
How does Sepranolone work?
Pharmacokinetic effects
Safety profile
The Sepranolone story
Tourette Syndrome
What is Tourette?
Sepranolone and Tourette
Publications
MEET CONSULTANT NEUROLOGIST DR HEIDI BIERNAT
Meet Prof Marco Bortolato
Meet TAA CEO Amanda Talty
Commercial potential
OCD
OCD
ALLOPREGNANOLONE AND OCD
Voices from the front line
SEPRANOLONE, CONTROL AND COMPULSION
PMDD
What is PMDD?
5 PMDD Myths
Sepranolone and PMDD
Phase IIb post-hoc analysis
Publications
Navigation Menu
Science
ALLO and GABA
GAMSAs
The GABA-A Receptor
Sepranolone
What is Sepranolone?
ALLO and GABA
How does Sepranolone work?
Pharmacokinetic effects
Safety profile
The Sepranolone story
Tourette Syndrome
What is Tourette?
Sepranolone and Tourette
Publications
MEET CONSULTANT NEUROLOGIST DR HEIDI BIERNAT
Meet Prof Marco Bortolato
Meet TAA CEO Amanda Talty
Commercial potential
OCD
OCD
ALLOPREGNANOLONE AND OCD
Voices from the front line
SEPRANOLONE, CONTROL AND COMPULSION
PMDD
What is PMDD?
5 PMDD Myths
Sepranolone and PMDD
Phase IIb post-hoc analysis
Publications
Investors
Press Releases
About Us
Contact
Annual general meeting June 30th 2026
Kallelse till årsstämma i Asarina Pharma AB (publ) i likvidation
Download
Rösträttsfullmakt
Download
Årsredovisning
Download
Revisionsberättelse
Download